Combination cisplatin and dichloromethotrexate in patients with advanced bladder cancer. Phase 2. A Southwest Oncology Group study.
Combination cisplatin and dichloromethotrexate in patients with advanced bladder cancer. Phase 2. A Southwest Oncology Group study.
复制标题
顺铂和二氯甲氨蝶呤联合治疗晚期膀胱癌。
DOI:
10.1016/s0022-5347(17)36506-0
复制
发表时间:
1992
期刊:
影响因子:
--
通讯作者:
Natale,RB
中科院分区:
文献类型:
--
作者:
Meyers,FJ;Blumenstein,B;Crawford,ED;Hynes,HE;Montie,JE;Taylor,SA;Grossman,HB;Natale,RB
The combination of cisplatin and dichloromethotrexate is a pharmacologically rational strategy designed to avoid the nephrotoxicity associated with the systemic chemotherapy of bladder cancer. Of 97 patients with metastatic bladder cancer entered into this study 73 with good renal function received cisplatin and dichloromethotrexate, while 24 with impaired renal function received dichloromethotrexate alone. No responses were noted in the latter group. A 42% response rate (95% exact confidence interval 30.0 to 55.2%), including 9 patients (14%) who achieved a complete response, was observed in the combination group. The toxicity patterns in both groups of patients were consistent with the hypothesis that renal toxicity would be ameliorated with the use of the methotrexate analogue. However, the failure to achieve a higher overall response rate despite near maximum tolerated doses of dichloromethotrexate discourages future studies with this agent. New agents for metastatic bladder cancer should be tested as first line therapy.
登录
查看更多内容
影响因子:
6.6
作者:
TANNOCK, I;GOSPODAROWICZ, M;JEWETT, M
通讯作者:
JEWETT, M
影响因子:
2.1
作者:
M. Brausi;A. Blatnik;M. Soloway
通讯作者:
M. Soloway
DOI:
--
发表时间:
1987
期刊:
NCI monographs : a publication of the National Cancer Institute
影响因子:
--
作者:
Natale,RB;Wheeler,RH;Roberts,JA
通讯作者:
Roberts,JA
影响因子:
45.3
作者:
D. Ettinger
通讯作者:
D. Ettinger
DOI:
10.1016/s0022-5347(17)49106-3
发表时间:
1985
期刊:
The Journal of urology
影响因子:
--
作者:
Ahmed,T;Yagoda,A;Needles,B;Scher,HI;Watson,RC;Geller,N
通讯作者:
Geller,N